Cardiology is a monthly peer-reviewed medical journal published by S. Karger AG in Basel, covering clinical, preclinical and translational research on diseases of the heart and the circulation.《心脏病学》（Cardiology）是瑞士巴塞尔 S. Karger AG 出版的同行评审月刊，覆盖心脏与循环系统疾病的临床、临床前及转化研究。
It reports original investigations, topical reviews and expert commentary, and its 2025 Journal Impact Factor of 1.9 places it in the third quartile of the cardiac and cardiovascular systems category.该刊刊发原创研究、专题综述与专家评论，2025 年影响因子为 1.9，在心脏与心血管系统类目处于第三四分位。
Scope
Coronary artery disease and acute coronary syndromes take the largest single share of clinical content, spanning diagnostic pathways, risk stratification and outcomes after revascularisation.冠心病与急性冠脉综合征占据临床稿件的最大份额，内容涉及诊断路径、危险分层以及血运重建后的结局。
Heart failure papers run from acute decompensation and intensive care management to long-term device therapy and the organisation of outpatient follow-up clinics.心力衰竭稿件从急性失代偿与重症监护处理，一直延伸到器械治疗与门诊随访体系的组织方式。
Arrhythmia and electrophysiology coverage includes atrial fibrillation, ventricular tachyarrhythmias, ablation strategy, and the programming and complications of implanted rhythm devices.心律失常与电生理方向涵盖心房颤动、室性快速心律失常、消融策略，以及植入型节律器械的程控与并发症。
Valvular heart disease is discussed through transcatheter and surgical intervention, echocardiographic grading, and the timing of operation in asymptomatic patients.瓣膜病方向的稿件讨论经导管与外科干预、超声心动图分级，以及无症状患者的手术时机。
Cardiomyopathies and other myocardial disease are treated with attention to imaging phenotypes, genetic substrate, and the boundary between inflammatory and infiltrative forms.心肌病与其他心肌疾病稿件关注影像表型、遗传基础，以及炎症性与浸润性病变之间的界限。
Cardiovascular imaging runs through echocardiography, cardiac magnetic resonance, computed tomography and nuclear techniques, judged on clinical decision value rather than technical performance alone.心血管影像覆盖超声心动图、心脏磁共振、计算机断层与核素技术，评价重点多落在临床决策价值而非单纯的成像性能。
Catheter-based intervention appears with procedural technique, device selection and registry data, including the handling of calcified lesions and bifurcation disease.介入治疗类稿件记录操作技术、器械选择与注册研究数据，涉及钙化病变与分叉病变的处理。
Prevention and risk stratification draw on lipid management, hypertension control, diabetes and lifestyle epidemiology, with emphasis on recalibrating risk scores for contemporary populations.预防与危险分层涉及血脂管理、血压控制、糖尿病与生活方式流行病学，重点在于为当代人群重新校准风险评分。
Cardiovascular pharmacology is represented by trials of antithrombotic agents and lipid-lowering drugs, by heart failure therapeutics, and by the practical problem of polypharmacy in elderly patients.心血管药理学以抗栓药物与降脂药物的试验为主，也收录心力衰竭治疗研究，并讨论老年患者多重用药的实际问题。
Congenital heart disease is followed from foetal diagnosis through paediatric catheterisation to the adult survivor population, which keeps growing as surgical survival improves.先天性心脏病从胎儿诊断、儿童期导管治疗一直写到成年存活人群，后者随外科生存率提高而持续扩大。
Thrombocardiology, a heading the journal has kept since the Heart Drug merger, deals with platelet function, anticoagulation and bleeding risk around percutaneous procedures.血栓心脏病学是该刊并入《Heart Drug》之后保留的方向，讨论血小板功能、抗凝治疗与经皮操作前后的出血风险。
Biomarker studies examine troponin, natriuretic peptides and inflammatory markers as diagnostic aids, and reviewers usually ask authors to show incremental value over established clinical variables.生物标志物研究考察肌钙蛋白、利钠肽与炎症指标在诊断中的辅助作用，审稿人多要求作者证明其相对于既有临床变量的增量价值。
Case reports, single-centre registries and preclinical models appear in smaller numbers, leaving room for uncommon presentations and for mechanistic work that has not yet reached trial stage.病例报告、单中心注册研究与临床前模型数量较少，为少见表现以及尚未进入试验阶段的机制研究留出空间。
History
The journal began in 1937 as Cardiologia, founded in Basel by Bruno Kisch and Wilhelm Löffler and printed under the Karger imprint that still carries it today.本刊 1937 年以《Cardiologia》之名在巴塞尔创刊，创办人为 Bruno Kisch 与 Wilhelm Löffler，出版方 Karger 至今未变。
Cardiologia ran for 54 volumes until 1969 and served as the organ of the Swiss and Swedish cardiac societies from 1948 and of the Dutch society from 1949, all three ties ending in 1967.《Cardiologia》共出 54 卷，至 1969 年止，1948 年起充任瑞士与瑞典两家心脏病学会的会刊，1949 年荷兰学会加入，三项关系均止于 1967 年。
The present title was adopted in 1970, when volume numbering resumed at 55 instead of restarting, so current volumes descend directly from the 1937 founding series.1970 年启用现名，卷号并未从头开始，而是接续第 55 卷，现行卷次由此直承 1937 年的创刊序列。
In 2005 the journal absorbed Heart Drug, a companion title on antithrombotic therapy, and has since carried thrombocardiology as one of its standing subject areas.2005 年该刊并入同属抗栓治疗领域的《Heart Drug》，血栓心脏病学自此成为常设方向之一。
Publication frequency has shifted several times, from twelve issues a year up to 1996 through eight issues from 1997 to the present arrangement of two volumes of six issues each.刊期几经调整，1996 年以前每年 12 期，1997 年起改为每年 8 期，现为每年两卷、每卷 6 期，合共 12 期。
An online edition carries the eISSN 1421-9751, and supplements have accompanied some volumes over the years.电子版以 eISSN 1421-9751 发行，部分卷次另出附刊。
MEDLINE coverage is recorded from volume 45, number 2 of 1964, an entry inherited from the predecessor title, and Index Medicus listed the journal for most of its run.MEDLINE 的收录起点记为 1964 年第 45 卷第 2 期，此条沿自前身刊，Index Medicus 亦长期著录本刊。
The journal sits in the Science Citation Index Expanded and, in the 2025 release, holds third quartile rank in cardiac and cardiovascular systems at position 151 of 237.本刊收录于 Science Citation Index Expanded，2025 年榜单在心脏与心血管系统类目列第三四分位，排名 151/237。
Impact factors have stayed modest and uneven, moving from 1.869 in 2021 to 2.342 in 2022, then 1.9 in 2023, 1.7 in 2024 and 1.9 in 2025, with a five-year figure of 1.9.影响因子多年在 1.7 至 2.3 之间浮动，2021 年为 1.869，2022 年 2.342，2023 年 1.9，2024 年 1.7，2025 年回到 1.9，五年值同为 1.9。
Roughly 73 articles appear each year, and about 2,491 citations were credited to the title in the 2025 report, against a cited half-life of 10.3 years.每年刊出约 73 篇论文，2025 年报告计得被引约 2491 次，总被引半衰期为 10.3 年。
Access is hybrid, with subscription content as the default while gold open access accounts for 37.39 per cent of what the journal publishes.访问模式为混合制，订阅内容仍为主体，金色开放获取占发文量的 37.39%。
Bibliographic registration is Swiss, the imprint naming Basel and New York, with CODEN CAGYAO and a record in the NLM catalog under ISSN 0008-6312.书目登记归属瑞士，出版地标为巴塞尔与纽约，CODEN 为 CAGYAO，美国国家医学图书馆目录以 ISSN 0008-6312 著录。
A cumulative index to volumes 1 to 30 appeared with volume 30, and from 1981 the journal was also indexed in the Combined Cumulative Index to Cardiology.第 30 卷随刊附有第 1 至 30 卷的累积索引，1981 年起另被《Combined Cumulative Index to Cardiology》收录。
Editors
Dan Atar of Oslo University Hospital holds the editor-in-chief position, with Trygve S. Hall, also in Oslo, running the editorial office as managing editor.主编为奥斯陆大学医院的 Dan Atar，同院的 Trygve S. Hall 任执行编辑，负责编辑部日常事务。
Associate editors are appointed by subspecialty rather than by geography, and each screens submissions and selects reviewers within a defined clinical area.副编辑按亚专科而非地域聘任，各自在划定的临床领域内初筛稿件并遴选审稿人。
Coronary artery disease and acute myocardial infarction are the responsibility of Lene Holmvang at Rigshospitalet in Copenhagen.冠心病与急性心肌梗死方向由哥本哈根 Rigshospitalet 的 Lene Holmvang 负责。
Heart failure and intensive care belong to Janina Stepinska of the Institute of Cardiology in Warsaw, a remit covering ward management and coronary care units alike.心力衰竭与重症监护由华沙心脏病研究所的 Janina Stepinska 分管，范围含病房管理与冠心病监护单元。
Cardiovascular imaging is assigned to Geneviève Derumeaux at Hôpital Henri Mondor near Paris, taking in echocardiography, magnetic resonance and computed tomography submissions.心血管影像由巴黎近郊 Hôpital Henri Mondor 的 Geneviève Derumeaux 分管，涵盖超声心动图、磁共振与计算机断层稿件。
Pyotr G. Platonov of Lund University takes electrophysiology and arrhythmia, a portfolio that includes ablation, device therapy and the epidemiology of sudden cardiac death.隆德大学的 Pyotr G. Platonov 分管电生理与心律失常，涉及消融、器械治疗与心源性猝死的流行病学。
Prevention and cardiovascular risk sit with Furio Colivicchi of San Filippo Neri Hospital in Rome, whose section covers lipids, blood pressure and smoking cessation programmes.预防与心血管风险由罗马 San Filippo Neri 医院的 Furio Colivicchi 负责，该方向涉及血脂、血压与戒烟项目。
Valvular heart disease has two editors, José L. Zamorano of University Hospital Ramón y Cajal in Madrid and Ricardo Fontes Carvalho of Gaia Hospital Center in Portugal.瓣膜病设两位副编辑，分别为马德里拉蒙-卡哈尔大学医院的 José L. Zamorano 与葡萄牙盖亚医院中心的 Ricardo Fontes Carvalho。
Biomarkers are handled by Petr Jarolim at Brigham and Women's Hospital in Boston, while thrombocardiology belongs to Victor L. Serebruany of Johns Hopkins University.生物标志物由波士顿布莱根妇女医院的 Petr Jarolim 分管，血栓心脏病学则由 Johns Hopkins University 的 Victor L. Serebruany 负责。
Manuscripts arrive through Karger's online system and are reviewed single blind, with the assigned associate editor deciding first and the editor-in-chief arbitrating contested cases.稿件经 Karger 在线系统投递，采用单盲评审，由分管副编辑作出初审决定，争议稿件交由主编裁定。
Editorials and correspondence sit alongside full articles, giving the board room to comment on trial results and on papers published elsewhere in the field.社论与读者来信同全文并列刊出，编委会借此评论试验结果，也回应本领域其他刊物发表的论文。